Nicholas Investment Partners’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Nicholas Investment Partners’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-40,941	Closed	-$2.03M	–	356
2015 Q2	$2.03M	Sell	40,941 -13,142	-24%	-$786K	0.13%	260
2015 Q1	$4.24M	Buy	54,083 +9,210	+21%	+$571K	0.26%	153
2014 Q4	$2.72M	Sell	44,873 -5,213	-10%	-$262K	0.17%	212
2014 Q3	$2.13M	Buy	50,086 +16,236	+48%	+$872K	0.13%	231
2014 Q2	$2.09M	Buy	33,850 +4,969	+17%	+$289K	0.12%	230
2014 Q1	$1.88M	Buy	+28,881	New	+$1.95M	0.16%	220

Other funds holding OREX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nicholas Investment Partners's OREX Position: Q3 2015 in Review

Nicholas Investment Partners sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 40,941 shares — an estimated $2.03M sold.

Nicholas Investment Partners first reported a position in OREX in Q1 2014 and held it in 6 quarters. The position peaked at $4.24M in Q1 2015. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

Nicholas Investment Partners reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Nicholas Investment Partners sold 40,941 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $2.03M.
Nicholas Investment Partners first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 6 quarters.
Nicholas Investment Partners's Orexigen Therapeutics, Inc. position peaked at $4.24M in Q1 2015.
132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Nicholas Investment Partners's 13F filing for Q3 2015, filed 17 Nov 2015.